JPMorgan Chase & Co. Buys 109,174 Shares of Definitive Healthcare Corp. (NASDAQ:DH)

JPMorgan Chase & Co. grew its position in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) by 49.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 331,264 shares of the company's stock after purchasing an additional 109,174 shares during the quarter. JPMorgan Chase & Co. owned about 0.29% of Definitive Healthcare worth $1,361,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DH. 272 Capital LP lifted its stake in Definitive Healthcare by 74.8% in the third quarter. 272 Capital LP now owns 1,114,080 shares of the company's stock valued at $4,980,000 after buying an additional 476,766 shares during the period. State Street Corp lifted its position in shares of Definitive Healthcare by 29.4% during the 3rd quarter. State Street Corp now owns 1,399,729 shares of the company's stock valued at $6,257,000 after acquiring an additional 317,952 shares during the period. PNC Financial Services Group Inc. boosted its stake in Definitive Healthcare by 928.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 156,997 shares of the company's stock worth $645,000 after acquiring an additional 141,729 shares in the last quarter. Barclays PLC grew its holdings in Definitive Healthcare by 318.8% in the third quarter. Barclays PLC now owns 81,916 shares of the company's stock worth $366,000 after purchasing an additional 62,354 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Definitive Healthcare by 35.9% in the fourth quarter. Bank of New York Mellon Corp now owns 229,143 shares of the company's stock valued at $942,000 after purchasing an additional 60,559 shares in the last quarter. Institutional investors and hedge funds own 98.67% of the company's stock.

Definitive Healthcare Stock Performance

Shares of NASDAQ DH traded up $0.06 during midday trading on Thursday, reaching $2.78. The company's stock had a trading volume of 33,310 shares, compared to its average volume of 849,694. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. The stock has a market capitalization of $299.60 million, a P/E ratio of -0.89, a PEG ratio of 4.06 and a beta of 1.48. The firm has a 50 day moving average price of $2.88 and a 200-day moving average price of $3.95. Definitive Healthcare Corp. has a 12-month low of $2.15 and a 12-month high of $7.47.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.07 by ($0.04). The business had revenue of $62.29 million for the quarter, compared to the consensus estimate of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. As a group, equities analysts predict that Definitive Healthcare Corp. will post 0.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DH shares. The Goldman Sachs Group decreased their target price on Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Finally, Barclays reduced their price target on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $5.35.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.